Claims

1. A pharmaceutical liposomal formulation, **characterized in that** it comprises as active ingredient a 3-amidino- or 3-guanidino-phenylalanine derivative effective as urokinase inhibitor.

2. The formulation as claimed in claim 1, **characterized in that** the urokinase inhibitor is selected from Nα-(2,4,6-triisopropylphenyl-sulfonyl)-3-amidino-(D,L)-phenylalanine-4-ethoxy-carbonylpiperazide, the L enantiomer thereof or a pharmaceutically acceptable salt of these compounds.

3. The formulation as claimed in claim 1, **characterized in that** the urokinase inhibitor is selected from Nα-(2,4,6-triisopropylphenyl-sulfonyl)-3-guanidino-(D,L)-phenylalanine-4-ethoxycarbonylpiperazide, the L enantiomer thereof or a pharmaceutically acceptable salt of these compounds.

4. The formulation as claimed in any of claims 1 to 3, **characterized in that** the active ingredient is present in a proportion by weight of 0.5-10% based on the total weight of the formulation.

5. The formulation as claimed in claim 4, **characterized in that** the active ingredient is present in a proportion by weight of 2-5%.

6. The formulation as claimed in any of claims 1 to 5, **characterized in that** it has a pH in the range 5.5-9.0.

7. The formulation as claimed in any of claims 1 to 6, **characterized in that** it comprises phospholipids in a proportion by weight of 4.5-40% based on the total weight of the formulation.

8. The formulation as claimed in any of claims 1 to 7, **characterized in that** it comprises phospholipids selected from neutral phospholipids, anionic phospholipids and combinations thereof.

9. The formulation as claimed in any of claims 1 to 8, **characterized in that** it comprises at least one anionic phospholipid such as, for example, phosphatidylethanolamine, phosphatidylglycerol, diphosphatidylglycerol, phosphoinositol or esterified derivatives thereof.

10. The formulation as claimed in claim 8 or 9, **characterized in that** it comprises phosphatidylcholine and dimyristoylphosphatidyl-glycerol in a ratio of 70:30 by weight.

11. The formulation as claimed in any of claims 1 to 10, **characterized in that** it additionally comprises a membrane-stabilizing component such as, for example, cholesterol, in a proportion by weight of up to 5% based on the total weight of the formulation.

12. The formulation as claimed in any of claims 1 to 11, **characterized in that** it additionally comprises a cryoprotectant.

13. The formulation as claimed in claim 12, **characterized in that** the cryoprotectant is present in a proportion by weight of up to 15%, preferably 5-15%, based on the total weight of the formulation.

14. The formulation as claimed in either of claims 12 or 13, **characterized in that** the cryoprotectant is selected from carbohydrates or/and sugar alcohols.

15. The formulation as claimed in any of claims 1 to 14, **characterized in that** the average diameter of liposomes is not greater than 500 nm.

16. The formulation as claimed in claim 15, **characterized in that** the average diameter of liposomes is 100-250 nm.

17. The formulation as claimed in any of claims 1 to 17, **characterized in that** the liposomes are unilamellar liposomes.

18. The formulation as claimed in any of claims 1 to 17 for parenteral administration.

19. The formulation as claimed in claim 18 for intravenous injection.

20. The formulation as claimed in claim 18 for infusion.

21. The formulation as claimed in claim 18 for subcutaneous injection.

22. The formulation as claimed in claim 18 for intramuscular injection.

23. The formulation as claimed in any of claims 1 to 22 in dehydrated form.

24. The formulation as claimed in any of claims 1 to 23 for controlling urokinase-associated disorders.

25. The formulation as claimed in claim 24 for controlling tumors.

26. The formulation as claimed in claim 25 for controlling carcinomas of the breast, pancreatic carcinomas or/and the formation of metastases.

27. The use of a formulation as claimed in any of claims 1 to 26 in combination with cytostatic agents.